Abstract
Introduction
In the last few years, the advent of targeted therapy and immunotherapy has improved the management and the prognosis of metastatic melanoma, but the spread of resistance mechanisms can lead to disease progression. The clinical management in this setting can be challenging because the oncologist has to decide what is the best treatment strategy among therapy beyond progression (TBP), therapy change, and the rechallenge approach. This review of the relevant scientific literature is intended to clarify which patients with progressing metastatic melanoma will benefit from continuation of ongoing therapy and which ones will not. The data are based on a total of about 4300 patients coming from the main retrospective studies in the chosen field. The article body is divided into four sections which analyze respectively the targeted therapy beyond progression, the immunotherapy beyond progression, the possible treatment sequences, and finally the rechallenge strategy.
Recent Findings
Despite the possible approaches of TBP or rechallenge, the patient may not have an optimal response and may need new therapy, which is currently missing. To broaden the pharmacological offer in the fight against melanoma, cancer research is studying new disease targets, like the NRAS, PI3K, and cKIT pathways or combination treatment of targeted therapy plus immunotherapy.
Summary
Despite the limitations of this work, mainly due to the limited number of studies, their retrospective nature and the lack of comparative studies, the analysis performed allows us to draw some important conclusions: therapy beyond progression, both targeted therapy and immunotherapy, represents a valid treatment option with positive effects on disease control and survival outcomes for patients with low clinical risk, expressed as low disease burden, normal LDH levels, and good performance status; moreover, the prognosis and quality of life of these patients improve when TBP is associated with locoregional treatments. In patients with progressive metastatic melanoma and high clinical risk (high disease burden, high LDH levels, and poor performance status), it is recommended to change therapy, without ever forgetting the possibility of enrolling the patient in a clinical trial. Finally, an efficacious treatment alternative is the rechallenge strategy; this approach consists in a re-treatment with the same drug after a variable interval of discontinuation. Preliminary studies seem to have demonstrated that patients retreated with targeted therapy achieved a greater benefit if they had a low clinical risk and if the drug doublet (BRAF + MEK inhibitors) was used. On the side of immunotherapy, the rechallenge strategy produced a major benefit in patients who prior experienced a severe toxic episode.
Similar content being viewed by others
References
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
Global Cancer Obseravatory – International Agency for Research on Cancer http://gco.iarc.fr/.
Rigel DS. Epidemiology of melanoma. Semin Cutan Med Surg. 2010;29(4):204–9. https://doi.org/10.1016/j.sder.2010.10.005.
Gandini S, Sera F, Cattaruzza MS, Pasquini P, Picconi O, Boyle P, et al. Meta-analysis of risk factors for cutaneous melanoma: II. Sun exposure. Eur J Cancer. 2005;41(1):45–60. https://doi.org/10.1016/j.ejca.2004.10.016.
Olsen CM, Carroll HJ, Whiteman DC. Estimating the attributable fraction for cancer: a meta-analysis of nevi and melanoma. Cancer Prev Res (Phila). 2010;3(2):233–45. https://doi.org/10.1158/1940-6207.CAPR-09-0108.
Sandru A, Voinea S, Panaitescu E, Blidaru A. Survival rates of patients with metastatic malignant melanoma. J Med Life. 2014;7(4):572–6 PMC4316142.
Eroglu Z, Ribas A. Combination therapy with BRAF and MEK inhibitors for melanoma: latest evidence and place in therapy. Ther Adv Med Oncol. 2016;8(1):48–56. https://doi.org/10.1177/1758834015616934.
Simeone E, Ascierto P. Anti-PD-1 and PD-L1 antibodies in metastatic melanoma. Melanoma Manag. 2017;4(4):175–8. https://doi.org/10.2217/mmt-2017-0018.
Van Allen EM, Wagle N, Sucker A, Treacy DJ, Johannessen CM, Goetz EM, et al. The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. Cancer Discov. 2014;4(1):94–109. https://doi.org/10.1158/2159-8290.CD-13-0617.
Borcoman E, Kanjanapan Y, Champiat S, Kato S, Servois V, Kurzrock R, et al. Novel patterns of response under immunotherapy. Ann Oncol. 2019;30(3):385–96. https://doi.org/10.1093/annonc/mdz003.
Chan MM, Haydu LE, Menzies AM, Azer MW, Klein O, Lyle M, et al. The nature and management of metastatic melanoma after progression on BRAF inhibitors: effects of extended BRAF inhibition. Cancer. 2014;120(20):3142–53. https://doi.org/10.1002/cncr.28851This paper represents one of the first studies as well as one of the most important on the topic of treatment beyond progression in patients with BRAF-mutated metastatic melanoma.
Hassel JC, Buder-Bakhaya K, Bender C, Zimmer L, Weide B, Loquai C, et al. Progression patterns under BRAF inhibitor treatment and treatment beyond progression in patients with metastatic melanoma. Cancer Med. 2018;7(1):95–104. https://doi.org/10.1002/cam4.1267.
Queirolo P, Spagnolo F, Picasso V, Spano L, Tanda E, Fontana V, et al. Combined vemurafenib and fotemustine in patients with BRAF V600 melanoma progressing on vemurafenib. Oncotarget. 2018;9(15):12408–17. https://doi.org/10.18632/oncotarget.10589.
Beaver JA, Hazarika M, Mulkey F, Mushti S, Chen H, He K, et al. An FDA pooled analysis of patients with melanoma treated with an Anti-PD1 antibody beyond RECIST progression. Lancet Oncol. 2018;19(2):229–39. https://doi.org/10.1016/S1470-2045(17)30846-XThis article, based on a large sample of patients, is the reference work for the study of immunotherapy beyond progression in metastatic melanoma.
McDermott D, Haanen J, Chen TT, Lorigan P, O'Day S. MDX010-20 Investigators. Efficacy and safety of ipilimumab in metastatic melanoma patients surviving more than 2 years following treatment in a phase III trial. Ann Oncol. 2013;24(10):2694–8. https://doi.org/10.1093/annonc/mdt291.
Schvartsman G, Taranto P, Glitza IC, Agarwala SS, Atkins MB, Buzaid AC. Management of metastatic cutaneous melanoma: updates in clinical practice. Ther Adv Med Oncol. 2019;11:1–16. https://doi.org/10.1177/1758835919851663.
Kreft S, Gesierich A, Eigentler T, Franklin C, Valpione S, Ugurel S, et al. Efficacy of PD-1–based immunotherapy after radiologic progression on targeted therapy in stage IV melanoma. Eur J Cancer. 2019;116:207–15. https://doi.org/10.1016/j.ejca.2019.05.015.
Ochoa CE, Joseph RW. Utility of ipilimumab in melanoma patients who progress on anti-PD-1 therapy. Melanoma Manag. 2017;4(3):143–5. https://doi.org/10.2217/mmt-2017-0010.
Gupta A, Gomes F, Lorigan P. The role for chemotherapy in the modern management of melanoma. Melanoma Manag. 2017;4(2):125–36. https://doi.org/10.2217/mmt-2017-0003.
Wróbel S, Przybyło M, Stępień E. The clinical trial landscape for melanoma therapies. J Clin Med. 2019;8(3):368. https://doi.org/10.3390/jcm8030368This paper highlights the importance of clinical trials as a treatment option in patients with progressing metastatic melanoma.
Hanovich E, Asmis T, Ong M, Stewart D. Rechallenge strategy in cancer therapy. Oncology. 2020:1–11. https://doi.org/10.1159/000507816.
Tonini G, Imperatori M, Vincenzi B, Frezza AM, Santini D. Rechallenge therapy and treatment holiday: different strategies in management of metastatic colorectal cancer. J Exp Clin Cancer Res. 2013;32(1):92. https://doi.org/10.1186/1756-9966-32-92.
Valpione S, Carlino MS, Mangana J, Gaba L, Long GV, Lorigan P, et al. Rechallenge with BRAF-directed treatment in metastatic melanoma: a multi-institutional retrospective study. Eur J Cancer. 2018;91:116–24. https://doi.org/10.1016/j.ejca.2017.12.007This work explains the rechallenge strategy with targeted therapy in advanced melanoma.
Reschke R, Ziemer M. Rechallenge with checkpoint inhibitors in metastatic melanoma. J Dtsch Dermatol Ges. 2020;18:429–36. https://doi.org/10.1111/ddg.14091This issue deals with the topic of rechallenge immunotherapy in metastatic melanoma.
Karachaliou N, Pilotto S, Teixido C, Viteri S, Gonzalez-Cao M, Riso A, et al. Melanoma: oncogenic drivers and the immune system. Ann Transl Med. 2015;3(18):265. https://doi.org/10.3978/j.issn.2305-5839.2015.08.06.
Kuske M, Westphal D, Wehner R, Schmitz M, Beissert S, Praetorius C, et al. Immunomodulatory effects of BRAF and MEK inhibitors: implications for melanoma therapy. Pharmacol Res. 2018;136:151–9. https://doi.org/10.1016/j.phrs.2018.08.019.
Hajek E, Krebs F, Bent R, Haas K, Bast A, Steinmetz I, et al. BRAF inhibitors stimulate inflammasome activation and interleukin 1 beta production in dendritic cells. Oncotarget. 2018;9(47):28294–308. https://doi.org/10.18632/oncotarget.25511.
Liu L, Mayes PA, Eastman S, Shi H, Yadavilli S, Zhang T, et al. The BRAF and MEK inhibitors dabrafenib and trametinib: effects on immune function and in combination with immunomodulatory antibodies targeting PD-1, PD-L1 and CTLA-4. Clin Cancer Res. 2015;21:1639–51. https://doi.org/10.1158/1078-0432.CCR-14-2339.
Long G, Lebbe C, Atkinson V, Mandalà M, Nathan PD, Fernandez AMA, et al. The anti–PD-1 antibody spartalizumab (S) in combination with dabrafenib (D) and trametinib (T) in previously untreated patients (pts) with advanced BRAF V600–mutant melanoma: Updated efficacy and safety from parts 1 and 2 of COMBI-i. J Clin Oncol. 2019;15:9531. https://doi.org/10.1200/JCO.2019.37.15_suppl.9531This study is considered one of the pioneering trials for development of combined treatment strategies in metastatic melanoma.
Glatzer M, Panje CM, Sirén C, Cihoric N, Putora PM. Decision making criteria in oncology. Oncology. 2020;98(6):370–8. https://doi.org/10.1159/000492272.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflicts of Interest
Francesco Serra, Stefania Barruscotti, Tommaso Dominioni, Andrea Zuccarini, and Paolo Pedrazzoli declare no conflict of interest. Silvia Chiellino has received compensation for service as a consultant from Bristol-Myers Squibb, MSD, and Novartis.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by the authors
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
This article is part of the Topical Collection on Melanoma
Supplementary Information
ESM 1
(DOCX 14 kb).
Rights and permissions
About this article
Cite this article
Serra, F., Barruscotti, S., Dominioni, T. et al. Treatment Following Progression in Metastatic Melanoma: the State of the Art from Scientific Literature to Clinical Need. Curr Oncol Rep 23, 84 (2021). https://doi.org/10.1007/s11912-021-01065-3
Accepted:
Published:
DOI: https://doi.org/10.1007/s11912-021-01065-3